Alex Zhavoronkov, PhD (aka Aleksandrs Zavoronkovs) ✓

@biogerontology · joined 12 Feb 2010

My posts are strictly personal, not reflective of positions or policies of Insilico Medicine, which disclaims any responsibility for my individual statements.

39 417Followers

1 798Following

15 372Posts total

13.4KViews on collected posts

Against accounts of the same size

11 posts from the last 90 days, next to the 10K–100K follower range. reaches fewer people than peers of the same size.

Median views664this account2 578median for 10K–100K

Reach, %1.68%this account7.77%median for 10K–100K

Engagement, %1.59%this account1.47%median for 10K–100K

Metric	This account	Median for 10K–100K	Ratio
Median views per post	664	2 578	0.26×
Reach (views ÷ followers)	1.68%	7.77%	0.22×
Engagement rate	1.59%	1.47%	1.08×

Others in this range → Compare with another account → How these benchmarks are built →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

3.1K25 Aug

389

664

4.2K2 Sep

118

643 Sep

1.2K

2.4K

1.2K

Last 11 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

1.12%25 Aug

0.26%

0.15%

2.76%2 Sep

0.00%

2.54%

4.69%3 Sep

0.00%

1.95%

3.57%

1.59%

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.47%.

What the audience does

Likes60.0%204 in total

Reposts15.3%52 in total

Replies7.9%27 in total

Quotes1.2%4 in total

Bookmarks15.6%53 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.

Latest posts

We published specialist AI models that outperform dedicated computational chemistry tools across 70+ benchmarks. ADMET, retrosynthesis, GPCR panels, kinase panels. General-purpose LLMs, fine-tuned right, now beat specialized scientific tools. 1.2K views · 13 likes · 1 reposts · 4 replies 03 Sep 2026 Semaglutide extended lifespan in aged female mice — Feng, Barthez et al., Danica Chen lab, in Nature today. 3 months of GLP-1R agonism at 20 months old improved function, dialed down hallmarks of aging, hit conserved nutrient-sensing pathways. Head-to-head vs calorie https://t.c 2.4K views · 54 likes · 23 reposts · 9 replies 03 Sep 2026 To explain a black-box medical image classifier, most counterfactual methods train a second black box (GAN/diffusion). This King's College London paper drops the generator, building counterfactuals from the classifier's causal evidence. 85% on brain MRI. https://t.co/oHljtEL6nQ 1.2K views · 18 likes · 5 reposts · 0 replies 03 Sep 2026 @biogerontology https://t.co/dsx02JmCQT 31 views · 0 likes · 0 reposts · 0 replies 03 Sep 2026 Roughly 10% to 20% of all recognized human diseases are directly caused by the total presence, absence, or structural alteration of a single, specific protein. However, if you broaden the scope to include conditions where a specific protein plays a primary causal driver (even if 64 views · 1 likes · 0 reposts · 1 replies 03 Sep 2026 @biogerontology Uhh it's an SGLT2 inhibitor. We already know it treats heart failure. Positive phase 3 trials, in guidelines, the whole deal. Chronic kidney disease and diabetes too. They don't cause much weight loss though. Hope the pandaomics finds something. 118 views · 2 likes · 0 reposts · 1 replies 02 Sep 2026 @biogerontology Depends on the biology. Repurposing works when the hits are mechanistically plausible, not just retrospective correlations in omics data. Good test case. 25 views · 0 likes · 0 reposts · 0 replies 02 Sep 2026 Most drug development goes: pick disease -> find molecule -> spend decade learning you were wrong. THPharm reversed it. THP-001 is already in global Phase 3. Now they're feeding its full biological fingerprint into PandaOmics to ask: what else does this drug treat? 16 dat 4.2K views · 94 likes · 14 reposts · 6 replies 02 Sep 2026 Panelists: Jeffrey Siegel (Director, Office of Drug Evaluation Sciences, CDER/FDA), Justin Penzenstadler (Associate Director, OCHEN/OND/CDER/FDA), Lowell M. Zeta (Acting Chief of Staff, Office of the Commissioner, FDA). Full program: https://t.co/J8vdGriSGu 664 views · 0 likes · 0 reposts · 1 replies 25 Aug 2026 ARDD 2026 comes to the US for the first time. October 1, 10:00-10:50: "Matching Clinical Trials of Therapeutics & Regulatory Mandates" - moderated by Dr. Andrew Brack (ARPA-H). Grateful to Dr. Brack for assembling and moderating this important panel. 389 views · 0 likes · 0 reposts · 1 replies 25 Aug 2026 As public demand for healthy longevity grows and pharma expands into aging-related indications, it is essential to keep the FDA in the dialogue. We are honored that FDA representatives will participate in the 13th Aging Research and Drug Discovery Meeting (ARDD 2026). https://t.c 3.1K views · 22 likes · 9 reposts · 4 replies 25 Aug 2026